105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Strengthens investment in channels of the future to expand patient reach
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
The company will offer Ventis Pharma’s patented local anesthetic compound, Endura-KitTM for post-operative surgical and chronic pain management
The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
Co-marketing agreement between Thermo Fisher Scientific and TransMIT allows for high spatial and high mass resolution MSI platform to study complex biological tissues
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
Subscribe To Our Newsletter & Stay Updated
